9/8/2023

Bumetanide Injection

Products Affected - Description

- Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 10 mL vial, 10 count, NDC 65219-0570-10
- Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 4 mL vial, 10 count, NDC 65219-0570-04
- Bumetanide injection, Hikma, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00641-6007-10

Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Glenmark has bumetanide injection available.
- Hikma did not provide a reason for the shortage.
- Pfizer has discontinued bumetanide injection in August 2022.
- Sagent acquired bumetanide from Athenex in June 2023. It is unclear when it will be available.

Available Products

- Bumetanide injection, Glenmark, 0.25 mg/mL, 10 mL vial, 10 count, NDC 68462-0470-54
- Bumetanide injection, Glenmark, 0.25 mg/mL, 4 mL vial, 10 count, NDC 68462-0469-54
- Bumetanide injection, Hikma, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00641-6008-10

Estimated Resupply Dates

- Fresenius Kabi has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on back order and the company estimates a release date of October 2023 for the 4 mL vials and September 2023 for the 10 mL vials.
- Hikma has bumetanide 0.25 mg/mL 10 mL vials on back order and the company estimates a release date of September 2023.

Updated

Updated September 8, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 23, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.